DVA Stock Summary and Trading Ideas (Davita | NYSE:DVA)

DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

Davita trades on the NYSE stock market under the symbol DVA.

As of November 6, 2026, DVA stock price declined to $191.35 with 490,863 million shares trading.

DVA has a beta of -0.46, meaning it tends to be less sensitive to market movements. DVA has a correlation of 0.01 to the broad based SPY ETF.

DVA has a market cap of $12.04 billion. This is considered a Large Cap stock.

Last quarter Davita reported $4 billion in Revenue and $3.82 earnings per share. This beat revenue expectation by $58 million and exceeded earnings estimates by $.20.

In the last 3 years, DVA traded as high as $247.49 and as low as $78.05.

The top ETF exchange traded funds that DVA belongs to (by Net Assets): RSP, VTI, VOO, VB, VBR.

DVA has outperformed the market in the last year with a price return of +57.5% while the SPY ETF gained +10.8%. DVA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.9% and +4.2%, respectively, while the SPY returned -4.1% and -3.2%, respectively.

DVA support price is $189.66 and resistance is $199.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DVA shares will trade within this expected range on the day.